18 results
To examine features of treatment response on optical coherence tomography in patients who were switched to aflibercept after non-response to previous intravitreal anti-VEGF treatment.
To determine the instantaneous effects of cerebellar tDCS during PFT on posturographical and neurophysiological parameters in stroke patients and healthy subjects.
Primary: to compare the treatment effect of ranibizumab PRN (visual acuity loss and/or SD-OCT disease activity guided retreatment) versus aflibercept bimonthly regimen on central retinal thickness stability as measured by mean fluctuations between…
The primary objective is to assess the effect of tDCS using different electrode configurations on corticomotor excitability in the lower extremities of chronic stroke survivors and healthy subjects. Secondary objectives are (a) to assess the effect…
Primary: To provide metastatic colorectal cancer patients with access to aflibercept and todocument the overall safety in these patientsSecondary: To document the Health-Related Quality of Life of aflibercept in this patientpopulation
We focus on a previous study showing enhanced motor sequence learning performance in OA when coupled with active tDCS stimulation. In their study, Zimerman et al. (2013) found a facilitating effect of M1 anodal tDCS on sequence learning in OA, these…
To evaluate the effects of tDCS on information processing speed in comparison to sham tDCS in patients after stroke with ascertained reduced processing speed. A proof of principle study.
The purpose of this study is to investigate how safe and effective the new drug conbercept given as intravitreal injections (*study drug*) is when compared with Eylea® injections in patients with neovascular *wet* age-related macular degeneration (…
Primary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg with respect to the change in best-corrected visual acuity (BCVA) from Baseline to Week 48Secondary:• To demonstrate that RTH258 6 mg is not inferior to aflibercept 2 mg…
The purpose of this study is to confirm how well aflibercept works in babies with ROP, comparing it with laser therapy. The study also has the objective to demonstrate how safe aflibercept is when used in babies. We will also learn how the drug…
To evaluate the efficacy and safety of brolucizumab used in a Treat-to-Control (TtC) regimen for the treatment of patients with neovascular age-related macular degeneration (nAMD) with the objective to evaluate the potential to reduce treatment…
In this study we want to find out how safe and effective is the new product brolucizumab. Brolucizumab is administered in this study to subjects with decreased sight due to diabetes macular edema. The effects of brolucizumab are compared with those…
This study will evaluate the effectiveness and safety of a 36-week refill regimen for the PDS with ranibizumab 100 mg/mL (PDS Q36W) compared with intravitreal injections of aflibercept (2 mg) administered per a treat-and-extend regimen (aflibercept…
The purpose of this study is to investigate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at up to 16-week intervals to treatment-naive patients with nAMD.
We aim to investigate the relationship between positive schema activation and subsequent tests of emotional schema memory, and whether tDSC during positive schema activation can facilitate retrieval of emotional memory for positive information in…
To determine the efficacy of intravitreal 2.0 mg OPT-302 when administered in combination with intravitreal 2.0 mg aflibercept, in participants with neovascular AMD.
To evaluate the efficacy and safety of brolucizumab in the treatment of patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO) and its potential to reduce the treatment burden for patients.
Primary Objective: Primary objective of this trial will be to determine whether iNPWT reduces the number of patients with clinically relevant* SSOs after (potentially) contaminated ventral hernia repair <30 days after surgery. *A SSO is…